Biopharma Insider Sales for Taxes
Crescent Biopharma Executives Sell Shares Under 10b5-1 Plans to Cover Vested Award Taxes
Key Points
CFO Richard William Scalzo’s post-sale stake sits at 20,298 Crescent Biopharma shares (about $365,161.02), after selling 1,112 shares on June 22.
COO Jonathan Mcneill’s post-sale stake is 139,158 Crescent Biopharma shares (approximately $2,503,452.42), after selling 20,549 shares on June 22.
Insider Ellie Eunkyung Im now holds 22,069 Crescent Biopharma shares (about $397,021.31) after selling 1,219 shares on June 22.
CEO Joshua Brumm’s stake stands at 281,212 Crescent Biopharma shares (roughly $5,059,003.88) after selling 42,305 shares on June 22.
Crescent Biopharma traded around $17.50 intraday with about 227,100 shares changing hands; the stock’s 50-day moving average is $19.83 and the 200-day moving average is $15.01, with a market cap around $482.3 million and a P/E of -1.60 (beta 1.17).
Four top executives at Crescent Biopharma (NASDAQ: CBIO) sold a combined 65,185 shares on June 22, cashing out roughly $1.17 million in stock, according to Investing.com. CEO Joshua Brumm led the group, unloading 42,305 shares for about $761,067 at a weighted average price of $17.99 per share.
The sales were made under Rule 10b5-1 plans — pre-set schedules that let insiders sell stock automatically to pay tax bills when restricted stock units vest. All four executives adopted these plans back in February 2026, well before the June transactions took place, according to SEC Form 4 filings.
Who Sold What and How Much Remains
CEO Joshua Brumm sold the most shares, cutting his stake by 13.08%. He still holds 281,212 shares worth roughly $5.06 million, according to Investing.com. COO Jonathan McNeill sold 20,549 shares for about $369,677, trimming his position by 12.87%. His remaining stake sits at 139,158 shares, valued near $2.5 million.
CFO Richard Scalzo sold just 1,112 shares for about $20,005, a 5.19% reduction. He now holds 20,298 shares. Chief Medical Officer Ellie Eunkyung Im sold 1,219 shares for about $21,930, leaving her with 22,069 shares. General Counsel Barbara Bispham also sold 1,218 shares under the same tax-cover plan, according to Watchlist News.
Stock Trades Below Its 50-Day Average
CBIO traded near $17.50 intraday on June 22, with about 227,100 shares changing hands. That price sits below the stock's 50-day moving average of $19.83 — a bearish signal for technical traders. However, it is well above the 200-day moving average of $15.01, suggesting longer-term momentum remains positive.
The company carries a market cap of roughly $482.3 million and a price-to-earnings ratio of -1.60, reflecting its pre-profit stage. Tickeron noted that the MACD — a momentum indicator — turned negative on June 2, flagging a possible downtrend even as most analysts maintain bullish ratings.
Analysts Divided on CR-001 Pipeline Potential
Crescent's lead drug, CR-001, is a bispecific antibody that blocks both PD-1 and VEGF — two proteins that help tumors grow and hide from the immune system. Stifel and Cantor Fitzgerald both rate the stock a Buy or Overweight, with price targets as high as $30.00, according to Investing.com. Cantor analysts said a recent Phase 3 failure by Pfizer in a similar drug class actually strengthens CR-001's position.
Not everyone is optimistic. H.C. Wainwright downgraded CBIO to Neutral, citing a crowded oncology market. The company's ASCEND Phase 1/2 trial data is not expected until Q1 2027, leaving investors with a long wait before any clinical proof of concept. Crescent posted a Q1 2026 loss of $0.70 per share, slightly better than estimates, on revenue of just $1.04 million.
Pre-Planned Tax Sales, Not a Vote of No Confidence
The key context here is timing. All five executives set up their 10b5-1 plans in late February 2026 — months before the June 22 sales. That gap matters because Rule 10b5-1 plans must be created when insiders do not hold material non-public information. The sales were triggered automatically when RSUs granted in December 2025 vested, according to Ticker Report.
Major institutional investors, including Forbion and OrbiMed, remain heavily invested in the company. That suggests large funds are looking past the tax-driven sales toward the 2027 data readout. Still, some retail investors note that the stock is trading below its 50-day average, adding a layer of unease around the timing.
Sentiment
Mostly NegativePublishers
10
Articles
9
Reach
19
